Maksymowych, Walter P. http://orcid.org/0000-0002-1291-1755
Lambert, Robert G. W.
Caplan, Liron
van den Bosch, Filip E.
Østergaard, Mikkel
Article History
Accepted: 29 April 2022
First Online: 13 May 2022
Competing interests
: W.P.M. is Chief Medical Officer of CARE Arthritis Limited, has acted as a paid consultant/participated in advisory boards for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB; received research and/or educational grants from AbbVie, Novartis, Pfizer and UCB; received speaker fees from AbbVie, Janssen, Novartis, Pfizer and UCB; and is a member of the ASAS-MRI Working Group. R.G.W.L. has consulted for AbbVie, CARE Arthritis, Parexel, Pfizer and UCB; and is a member of the ASAS-MRI Working Group. F.v.d.B. has received consultancy fees and/or speaker fees from AbbVie, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB Pharma. M.Ø. has received grant/research support from AbbVie, Bristol-Myers Squibb, Celgene, Merck and Novartis; has worked as a paid consultant for AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, CARE Arthritis, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo Nordisk, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB; and received speaker fees from AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Orion, Pfizer, Roche, Sandoz, Sanofi and UCB, and is a member of the ASAS-MRI Working Group. L.C. declares no competing interests.